TG Therapeutics (FRA:NKB2) Preferred Dividends : €0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is TG Therapeutics Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. TG Therapeutics's preferred dividends for the three months ended in Mar. 2025 was €0.0 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

TG Therapeutics Preferred Dividends Historical Data

The historical data trend for TG Therapeutics's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Preferred Dividends Chart

TG Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Preferred Dividends

Get a 7-Day Free Trial

TG Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

TG Therapeutics Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

TG Therapeutics (FRA:NKB2) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

TG Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (FRA:NKB2) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

TGTX:USA 0VGI:UK

Address

3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560

Website

https://www.tgtherapeutics.com

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines